Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts' consensus is "Hold": Six research firms cover Invivyd (1 sell, 2 hold, 3 buy) with an average 12‑month price target of $8.00.
• Shares trade low relative to the target (opened at $1.46; 12‑month range $0.48–$3.07) with a market cap of $412.9M, and insiders have been net sellers — 227,172 shares sold in the last 90 days while insiders still own 25.40% of the stock.
• Invivyd is a commercial‑stage biopharma focused on antibody solutions for infectious diseases, with a pipeline that includes PEMGRADA (pemivibart), preclinical VYD2311, and adintrvimab in Phase 3 trials for COVID‑19 prevention/treatment.

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.00.

A number of research analysts have commented on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research restated a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research note on Thursday, February 26th.

Invivyd Price Performance

Shares of IVVD opened at $1.46 on Friday. The stock's 50-day moving average is $1.58 and its two-hundred day moving average is $1.94. The stock has a market cap of $412.89 million, a PE ratio of -4.56 and a beta of 0.73. Invivyd has a 12 month low of $0.48 and a 12 month high of $3.07.

Insiders Place Their Bets

In related news, CFO William E. Duke sold 20,964 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the chief financial officer owned 107,717 shares in the company, valued at approximately $170,192.86. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Julie Green sold 20,964 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the transaction, the insider owned 107,717 shares in the company, valued at approximately $170,192.86. This trade represents a 16.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 227,172 shares of company stock valued at $354,534. Insiders own 25.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Courier Capital LLC bought a new stake in Invivyd in the fourth quarter valued at about $25,000. Bronte Capital Management Pty Ltd. bought a new stake in Invivyd in the fourth quarter valued at about $27,000. DRW Securities LLC bought a new stake in Invivyd in the fourth quarter valued at about $27,000. ProShare Advisors LLC bought a new stake in Invivyd in the fourth quarter valued at about $30,000. Finally, State of Wyoming bought a new stake in Invivyd in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.